Benitec Biopharma Inc
BNTC
Get informed when a big investor buys or sells
+ FollowMarket Cap$463.1M
Close$
$1.90
85.3% downside
Current Fair Value
85.3% downsideOvervalued by 85.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $463.10 Million |
|---|---|
| Enterprise Value | $279.21 Million |
| Dividend Yield | $0.77 (-) |
| Earnings per Share | $-1.05 |
| Beta | 0.26 |
| Outstanding Shares | 49,386,203 |
Return
| Return on Equity | -26.66% |
|---|---|
| Return on Assets | -26.14% |
| Return on Invested Capital | -30.22% |
Valuation & Multiples
| P/E Ratio | -12.14 |
|---|---|
| PEG | -44.01 |
| Price to Sales | - |
| Price to Book Ratio | 4.29 |
| Enterprise Value to Revenue | 502.18 |
| Enterprise Value to EBIT | -5.03 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 18, 2026
EPS Estimate
$-0.28
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
September 28, 2026
EPS Estimate
$-0.26
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 65.77%▼ 3.10% |
|---|---|
| Total Invested | $346.03M▼ 18.88% |
| Investors Holding | 88▲ 17.00% |
ESG Score
No data